|
www.aurobindo.com |
|
|
Hyderabad, February 28, 2007 |
|
|
|
Aurobindo receives NAM Finland
Approval for its facility at UNIT-VI |
|
|
Aurobindo is pleased to announce
that NAM (National Agency for Medicines),
Finland has approved its facility at Unit-VI to
manufacture Cefuroxime injectable 750mg and
1500mg. The Finnish authorities were satisfied
regarding the manufacturing practices at the
site and stated that it fulfills the prescribed
EU-GMP standards. |
|
This facility is situated on a
15-acre land in Chitkul village, Patancheru
mandal of Medak district. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company
has received approvals for most of the targeted
API and formulation facilities from leading
regulatory agencies like US FDA, UK MHRA, WHO,
Health Canada, MCC South Africa. The company’s
robust product portfolio is spread over 6 major
therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics. The
formulation portfolio is built on six technology
platforms such as immediate release generics,
SR/CR generics, Orally disintegrating/Mouth
dissolving generics, Combination products,
Sterile/Lyophilized generics and Liquids/Dry
syrups.
Aurobindo has filed over 100 DMFs
and 75 ANDAs for the USA market alone in
addition to filings in other countries. The pace
of filings is matched by rapid product approvals
from various markets. Till date Aurobindo
received 38 ANDA approvals (both final and
tentative) from US alone. Aurobindo operates in
over 100 countries and markets over 180 APIs and
250 formulations |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Mobile 0 98486 67906
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
